Technical Analysis for VTVT - vTv Therapeutics Inc.

Grade Last Price % Change Price Change
D 2.27 -1.73% -0.04
VTVT closed down 1.73 percent on Thursday, May 13, 2021, on 17 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical VTVT trend table...

Date Alert Name Type % Chg
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
180 Bearish Setup Bearish Swing Setup -1.73%
Inside Day Range Contraction -1.73%
Down 3 Days in a Row Weakness -1.73%
200 DMA Support Bullish -5.42%
Wide Bands Range Expansion -5.42%
Wide Bands Range Expansion -5.81%
Narrow Range Bar Range Contraction -8.10%
Older End-of-Day Signals for VTVT ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 2% about 13 hours ago
60 Minute Opening Range Breakout about 13 hours ago
Down 3% about 13 hours ago
Lower Bollinger Band Support about 13 hours ago
Down 2 % about 14 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


vTv Therapeutics Inc. Description

vTv Therapeutics Inc., a biopharmaceutical company, engages in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease includes azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials. The company's type 2 diabetes drug candidates comprise TTP399, an orally administered, liver-selective glucokinase activator, which is in a Phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor that has completed Phase I clinical trials. It is also developing HPP593, a functionally selective peroxisome proliferator-activated receptor delta agonist for the prevention of muscle weakness associated with prolonged mechanical ventilation and critical injury that has completed Phase Ib clinical trials; HPP737, an orally administered phosphodiesterase-4 inhibitor for the treatment of chronic obstructive pulmonary disease, psoriasis, and other inflammatory diseases, which has completed Phase Ib clinical trials; and HPP971, a Bach1 inhibitor, for the treatment of inflammation, autoimmune diseases, and diseases associated with oxidative stress, which is in Phase 1 clinical trials. The company has a license and research agreement with Calithera Biosciences, Inc. to research, develop, and commercialize its hexokinase II inhibitors for therapeutics, prophylactic, preventative, or diagnostic use. vTv Therapeutics Inc. was founded in 2015 and is headquartered in High Point, North Carolina.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Diseases Diabetes Autoimmune Diseases Inflammation Autoimmune Disease Injury Alzheimer's Disease Inflammatory Disease Inflammatory Diseases Parkinson's Disease Weakness Psoriasis Pulmonary Disease Organic Chemistry Chronic Obstructive Pulmonary Disease Pyridines Treatment Of Alzheimer's Disease Oxidative Stress Treatment Of Chronic Obstructive Pulmonary Disease Tyrosine Kinase Inhibitors Biotie Therapies Mechanical Ventilation Phosphodiesterase Treatment Of Inflammation Buparlisib

Is VTVT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 4.75
52 Week Low 1.44
Average Volume 6,197,583
200-Day Moving Average 2.23
50-Day Moving Average 2.64
20-Day Moving Average 2.48
10-Day Moving Average 2.43
Average True Range 0.19
ADX 14.07
+DI 17.44
-DI 26.01
Chandelier Exit (Long, 3 ATRs ) 2.77
Chandelier Exit (Short, 3 ATRs ) 2.79
Upper Bollinger Band 2.70
Lower Bollinger Band 2.26
Percent B (%b) 0.01
BandWidth 17.44
MACD Line -0.09
MACD Signal Line -0.07
MACD Histogram -0.0244
Fundamentals Value
Market Cap 117.67 Million
Num Shares 51.8 Million
EPS -0.56
Price-to-Earnings (P/E) Ratio -4.03
Price-to-Sales 4106.62
Price-to-Book 0.00
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.45
Resistance 3 (R3) 2.46 2.41 2.42
Resistance 2 (R2) 2.41 2.36 2.40 2.41
Resistance 1 (R1) 2.34 2.34 2.32 2.33 2.40
Pivot Point 2.29 2.29 2.28 2.29 2.29
Support 1 (S1) 2.22 2.24 2.20 2.21 2.14
Support 2 (S2) 2.17 2.22 2.17 2.13
Support 3 (S3) 2.10 2.17 2.12
Support 4 (S4) 2.09